Here demonstrated the contribution of other checkpoint molecules such as CD80 suggest that studies on the combinatory application of these protein inhibitors might be of great importance, especially considering different features of only seemingly the same types of breast cancers. The gene discussed is CD80; the disease is breast carcinoma.